Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Stage IV Squamous Cell Carcinoma of the Nasopharynx Clinical Trial

Official title:

Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01349933
• Other study ID #: NCI-2011-02581
• Secondary ID: NCI-2011-02581CD
• Status: Completed
• Phase: Phase 2
• First received: May 6, 2011
• Last updated: October 30, 2017
• Start date: April 2011
• Est. completion date: October 2013

Study information

• Verified date: October 2017
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with recurrent or metastatic head and neck cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Description:

PRIMARY OBJECTIVES:

I. To determine the proportion of patients alive and progression-free at 6 months along with the confirmed response rate as a dual primary endpoint..

SECONDARY OBJECTIVES:

I. To evaluate best response and duration of response for patients treated with MK2206 (Akt inhibitor MK2206).

II. To evaluate the overall survival and progression-free survival (PFS) of patients treated with MK2206.

III. To evaluate safety and tolerability of MK2206.

TERTIARY OBJECTIVES:

I. To evaluate the pharmacokinetics of MK2206 in Asian patients. II. To study the pharmacodynamic effect of MK2206 using biomarkers and correlation with cancer-related outcomes.

OUTLINE: This is a multicenter study.

Patients receive Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection at baseline and periodically during study for pharmacogenomic and pharmacokinetic studies.

After completion of study therapy, patients are followed up for up to 3 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed non-keratinizing nasopharyngeal carcinoma that has recurred at locoregional and/or distant sites, and is not amenable to potentially curative radiotherapy or surgery

• Measurable disease according to the RECIST criteria

• Progressed =< 24 months of receiving one or two prior line(s) of chemotherapy for recurrent disease, of which at least one line must contain platinum drugs such as cisplatin, carboplatin or oxaliplatin

• ECOG performance status 0, 1, or 2

• Hemoglobin >= 9 g/dL

• ANC >= 1,500/µL

• Platelet count >= 100,000/µL

• Total bilirubin =< 2.5 times upper limit of normal (ULN)

• ALT =< 2.5 times ULN (=< 5 times ULN for patients with liver metastases)

• Creatinine =< 1.5 times ULN OR creatinine clearance >= 60 mL/min/1.73 m^2

• Ability to understand and the willingness to sign a written informed consent document

• Willingness to donate blood for mandatory correlative research studies

• Negative (serum) pregnancy test done =< 7 days prior to registration, for women of childbearing potential only

Exclusion Criteria:

• Any of the following

• Chemotherapy =< 4 weeks prior to registration

• Radiotherapy =< 4 weeks prior to registration

• Nitrosoureas or Mitomycin C =< 4 weeks prior to registration

• Those who have not recovered from adverse events due to agents administered more than 4 weeks earlier

• NOTE: Prior palliative radiotherapy to bone metastases is allowed =< 4 weeks prior to registration

• Prior investigational agents =< 4 weeks prior to registration

• Symptomatic brain metastases; NOTE: primary nasopharyngeal cancers that directly invade the skull base and extend into the infratemporal fossa(e) are not regarded as brain metastases and are not excluded

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 or other agents used in the study

• Prior potent and moderate inhibitors and inducers of CYP3A4 =< 2 weeks prior to registration:

• Drugs that are forbidden, potent inducers of CYP3A4: phenytoin, phenobarbitone, carbamazepine, barbiturate, rifampicin, St John's Wort.

• Drugs that significantly affect metabolizing activity by way of enzyme inhibition of CYP3A4: ketoconazole, itraconazole, fluconazole, indinavir, ritonavir, erythromycin, cimetidine, clarithromycin

• Unwillingness to go off other inducers and inhibitors of CYP3A4 during the first 2 cycles of MK-2206; NOTE: avoiding these drugs is critical during the first 2 cycles of MK-2206when blood samples are being taken for the correlative study unless there is an urgent medical need and alternatives are not available

• Poorly controlled diabetes mellitus or insulin controlled diabetes; NOTE: As a general guide, patients with a fasting glucose level > 150 mg/dL (HbA1c <8%, > 8.3 mmol/L), or a random glucose level of >180mg/dL (> 10 mmol/L) is considered to have inadequately controlled diabetes and are not eligible for this study; however, such patients can become eligible in the future if their fasting glucose levels improve with medical treatment

• QTc prolongation (defined as a QTc interval > 450 msec for males and >470 msec for females) or other significant ECG abnormalities; NOTE: patients with clinically significant cardiac conduction abnormalities should be excluded, these include left bundle branch block (LBBB), 2nd or 3rd degree AV block, bifascicular block, sick sinus syndrome, Wolff-Parkinson-white syndrome, sinus bradycardia (< 50bpm); however, patients with asymptomatic right bundle branch block (RBBB) or 1st degree AV block, in the absence of known cardiac disease (e.g. coronary, valvular) are not excluded

• Uncontrolled intercurrent illness including, but not limited to:

• Ongoing or active infection,

• Symptomatic congestive heart failure,

• Unstable angina pectoris,

• Uncontrolled symptomatic cardiac arrhythmia,

• Psychiatric illness/social situations that would limit compliance with study requirements

• Diagnosed to have any of the following condition(s), and/or have undergone any one of the following procedure(s) =< 3 months prior to registration:

• Symptomatic thrombotic or hemorrhagic cerebral vascular accident

• Coronary bypass graft

• Angioplasty

• Myocardial infarction

• Patients having continuing >= grade 2 adverse events (excluding alopecia) due to agents (chemotherapy or radiotherapy) administered > 4 weeks prior to registration based on Common Terminology Criteria for Adverse Events (CTCAE version 4.0) =< grade 1

• Any of the following:

• Pregnant women

• Nursing women

• Men or women of childbearing potential who are unwilling to employ adequate contraception

• NOTE: because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MK-2206, breastfeeding should be discontinued if the mother is treated with MK-2206; women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

• HIV-positive patients on combination antiretroviral therapy; NOTE: HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MK-2206; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy

• Recent major surgery =< 4 weeks prior to registration (excluding the placement of vascular access), or minor surgery =< 2 weeks prior to registration

• Any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption) that impairs patients ability to swallow MK-2206 tablets

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Nasopharyngeal Neoplasms
• Recurrent Squamous Cell Carcinoma of the Nasopharynx
• Stage IV Squamous Cell Carcinoma of the Nasopharynx

Intervention

Drug:
• Akt inhibitor MK2206
Given PO

Locations

Country	Name	City	State
China	Chinese University of Hong Kong-Prince of Wales Hospital	Shatin	Hong Kong
Singapore	Johns Hopkins Singapore International Medical Centre	Singapore
Singapore	National Cancer Centre	Singapore
Singapore	National University Hospital	Singapore
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa
United States	Mayo Clinic	Rochester	Minnesota
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Metro-Minnesota CCOP	Saint Louis Park	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  China,  Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Patients Alive and Progression-free	The primary endpoint of this trial is the proportion of patients alive and progression-free at 6 months. Progression status is evaluated using RECIST version 1.1. A Progression is defined as either: At least one new malignant lesion, which also includes any lymph node that was normal at baseline (less than 1.0 cm short axis) and increased to greater than or equal to 1 cm short axis during follow up. Or, at least a 20% increase in sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes.	6 months
Primary	Confirmed Response Rate Defined to be a CR or PR Noted as the Objective Status on 2 Consecutive Evaluations at Least 4 Weeks Apart	Evaluated using RECIST version 1.1. A Complete Response (CR) requires disappearance of all target lesions and each target lymph node must have reduction in short axis to <1.0 cm. A Partial Response (PR) requires at least a 30% decrease in the sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation. The confirmed response rate is reported as the number of participants with confirmed responses divided by the number of evaluated participants.	6 months
Secondary	Adverse Events Associated With the Agent Graded Based on CTCAE Version 4.0	The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine adverse event patterns. Only the severe or worse adverse events will be assessed, regardless of relationship to the study treatment. The number of patients reporting a grade 3 or higher event were counted.	Up to 30 days after completion of study treatment
Secondary	Overall Survival	Estimated using the method of Kaplan-Meier.	From registration to death due to any cause, assessed up to 3 years
Secondary	Progression-free Survival	Progression-free survival is defined as the time from registration to the time of progression or death, whichever occurs first. Estimated using the method of Kaplan-Meier.	From registration to the first of either death due to any cause or progression, assessed up to 3 years
Secondary	Best Response (Complete Response vs Partial Response vs Stable Disease vs Progression)	Evaluated using RECIST version 1.1. A Complete Response (CR) requires disappearance of all target lesions and each target lymph node must have reduction in short axis to <1.0 cm. A Partial Response (PR) requires at least a 30% decrease in the sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation. Progressive Disease (PD) is defined as either a new lesion of a 20% increase in the sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes. Stable Disease (SD) is defined as not having a PD, CR, or PR.	Up to 3 years
Secondary	Duration of Response	Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented.	The date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented, assessed up to 3 years